HCA Healthcare Inks Deal to Buy Operations of Five Utah Hospitals

HCA Healthcare (HCA) has agreed to acquire the operations of Steward Health Care’s five hospitals in Utah. The financial terms of the deal have been kept under wraps. Shares of Read More... The post HCA Healthcare Inks Deal to Buy Operations of Five Utah Hospitals appeared first on TipRanks Financial Blog.

HCA Healthcare Inks Deal to Buy Operations of Five Utah Hospitals

HCA Healthcare (HCA) has agreed to acquire the operations of Steward Health Care’s five hospitals in Utah. The financial terms of the deal have been kept under wraps.

Shares of the leading provider of healthcare services facilities in the U.S. that operates 187 hospitals and approximately 2,000 care centers have gained 103% over the past year. (See HCA stock chart on TipRanks)

The addition of Steward Health Care hospitals will strengthen and diversify HCA Healthcare’s existing mountain division portfolio, which comprises 11 hospitals in Utah, Idaho and Alaska.

The CEO of HCA Healthcare, Sam Hazen, said, “Utah is one of the fastest-growing areas in the country, and the state’s need for healthcare continues to increase.”

He added, “We believe the addition of these facilities will help us improve healthcare network options for patients and enable investment in services to meet the increasing demand for healthcare.”

Further, HCA has inked another agreement with hospital owner Medical Properties Trust, Inc. (MPW) to lease all of MPW's Utah hospitals upon closing of the above transaction with Steward Health Care.

As per the terms of the 15-year master lease for the five Utah hospitals, the cash rent payable to MPW will be the same as the existing Steward master lease. Further, it includes five extension options of five years each, and rental payments will increase annually at CPI, subject to a 2% floor and 5% ceiling.

Additionally, from 2028, HCA Healthcare will have options to purchase the facilities from MPW at a purchase price not less than the fair value.

MPW purchased the Utah hospitals for $1.2 billion, and they represent around 5% of its total gross assets. Upon the completion of the agreement with HCA Healthcare, the percentage of Steward assets in MPW’s portfolio will decrease to nearly 17%.

Both transactions are expected to close in the first half of 2022, subject to certain approvals.

Recently, Cowen & Co. analyst Gary Taylor initiated coverage on HCA Healthcare with a Buy rating and a price target of $293 (12.8% upside potential).

Overall, the stock has a Strong Buy consensus rating based on 15 Buys and 3 Holds. The average HCA Healthcare price target of $273.89 implies 7.4% upside potential.

HCA scores a “Perfect 10” on TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations.

Related News:
Over 1M People Apply for Jobs at Amazon Career Day 2021
Sorrento Reports Positive Results for COVISTIX COVID-19 Detection
Brown & Brown Snaps up AGIS Network, Gremesco

The post HCA Healthcare Inks Deal to Buy Operations of Five Utah Hospitals appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dermata Therapeutics (DRMA) and Boston Scientific (BSX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dermata Therapeutics (DRMA – Research Report) and Boston Scientific (BSX – Research Report). Dermata Therapeutics (DRMA) Brookline Capital Markets analyst Kumaraguru Raja initiated coverage with a Buy rating on Dermata Therapeutics today and set a price target of $14.00. The company's shares closed last Tuesday at $5.16. According to TipRanks.com, Raja is a 4-star analyst with an average return of 16.0% and a 39.7% success rate. Raja covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Armata Pharmaceuticals, and Arcturus Therapeutics. Dermata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.50, implying a 143.1% upside from current levels. In a report issued on September 14, Maxim Group also initiated coverage with a Buy rating on the stock with a $9.00 price target. See today’s analyst top recommended stocks >> Boston Scientific (BSX) Needham analyst Michael Matson maintained a Hold rating on Boston Scientific today. The company's shares closed last Tuesday at $43.89. According to TipRanks.com, Matson is a 5-star analyst with an average return of 16.6% and a 64.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $59.85, implying a 36.0% upside from current levels. In a report issued on September 17, Leerink Partners also maintained a Hold rating on the stock with a $48.00 price target. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on DRMA: TD Bank Group, Yodlee Announce Data Access Agreement Cognyte Software Beats Estimates in Q2; Shares Fall 13.7% How Plug Power Goes to Positive $9 Billion in Revenue in 9 Years Zscaler Stock: Great Long-Term Play on Cybersecurity HCA Healthcare Inks Deal to Buy Operations of Five Utah Hospitals The post Analysts Have Conflicting Sentiments on These Healthcare Companies: Dermata Therapeutics (DRMA) and Boston Scientific (BSX) appeared first on TipRanks Financial Blog.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dermata Therapeutics (DRMA) and Boston Scientific (BSX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dermata Therapeutics (DRMA – Research Report) and Boston Scientific (BSX – Research Report).

Dermata Therapeutics (DRMA)

Brookline Capital Markets analyst Kumaraguru Raja initiated coverage with a Buy rating on Dermata Therapeutics today and set a price target of $14.00. The company's shares closed last Tuesday at $5.16.

According to TipRanks.com, Raja is a 4-star analyst with an average return of 16.0% and a 39.7% success rate. Raja covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Armata Pharmaceuticals, and Arcturus Therapeutics.

Dermata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.50, implying a 143.1% upside from current levels. In a report issued on September 14, Maxim Group also initiated coverage with a Buy rating on the stock with a $9.00 price target.

Boston Scientific (BSX)

Needham analyst Michael Matson maintained a Hold rating on Boston Scientific today. The company's shares closed last Tuesday at $43.89.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 16.6% and a 64.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $59.85, implying a 36.0% upside from current levels. In a report issued on September 17, Leerink Partners also maintained a Hold rating on the stock with a $48.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DRMA:

  • TD Bank Group, Yodlee Announce Data Access Agreement
  • Cognyte Software Beats Estimates in Q2; Shares Fall 13.7%
  • How Plug Power Goes to Positive $9 Billion in Revenue in 9 Years
  • Zscaler Stock: Great Long-Term Play on Cybersecurity
  • HCA Healthcare Inks Deal to Buy Operations of Five Utah Hospitals

The post Analysts Have Conflicting Sentiments on These Healthcare Companies: Dermata Therapeutics (DRMA) and Boston Scientific (BSX) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.